iCo Therapeutics focuses on rethinking and reformulating existing pharmaceutical candidates to address global health issues. The company operates in the pharmaceutical industry, targeting both systemic fungal and parasitic infections with innovative drug formulations. Their primary clients include healthcare providers and patients who benefit from improved drug efficacy and reduced adverse events. iCo Therapeutics generates revenue through the development and commercialization of these reformulated drugs, often partnering with other pharmaceutical companies for distribution and clinical testing. The company's business model leverages existing clinical data to reduce the risk and cost associated with new drug development. Recent advancements include the development of an oral formulation of Amphotericin B, which aims to offer significant advantages over traditional intravenous formulations. This new formulation could be particularly beneficial for immunocompromised patients, providing easier administration and fewer side effects. iCo Therapeutics has also received Fast Track designation for iCo 008, aimed at treating bullous pemphigoid, a rare skin condition.

Keywords: drug reformulation, global health, pharmaceutical innovation, Amphotericin B, oral formulations, immunocompromised patients, clinical testing, drug commercialization, healthcare providers, bullous pemphigoid.